KAIROS PHARMA, LTD. Number of Reportable Segments
KAIROS PHARMA, LTD. (KAPA) reported Number of Reportable Segments of 1 Integer for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:NumberOfReportableSegments · last filed 2026-08-12
- KAIROS PHARMA, LTD. number of reportable segments for the quarter ending 2026-03-31 was 1.00 Integer, a 0.00% change year-over-year.
- KAIROS PHARMA, LTD. number of reportable segments for the quarter ending 2025-03-31 was 1.00 Integer.
- KAIROS PHARMA, LTD. number of reportable segments for fiscal 2025 was 1.00 Integer, a 0.00% change from fiscal 2024.
- KAIROS PHARMA, LTD. number of reportable segments for fiscal 2024 was 1.00 Integer.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Integer 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 1.00 Integer 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 1.00 Integer 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 1.00 Integer 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 1.00 Integer 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | 1.00 Integer 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | 1.00 Integer 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |